Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Reminder: Xenon’s Annual Meeting of Shareholders will take place on Thursday, June 3, 2021 at 11:30 am PT / 2:30 pm ET. See more details here.
Read MoreNews
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
May 04, 2021
- Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
April 08, 2021
- Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
March 29, 2021
- Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2021
Product Pipeline
XEN1101
for Epilepsy
XEN496
for Epilepsy
XEN007
for Orphan Neurological Indications
NBI-921352
for Epilepsy
Partnered with Neurocrine Biosciences
FX301
for Post-Operative Pain
Partnered with Flexion Therapeutics
NAV1.7 Inhibitors
for Pain
Partnered with Genentech
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
